1World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: WHO Publication, 1999.
2The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003, 26:3160-3167.
3International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [ EB/OL]. [ 2006-11-01 ]. http://www. idf. org/home/index. cfm? node = 1429.
4Lebovitz HE, Banerji MA. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmaeol, 2004, 490 : 135-146.
5Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in β-cell function. Nature, 2001, 414 : 788- 791.
6Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001, 108 : 1167-1174.
7Lord JM, Hight IH, Norman RJ. Mefformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ, 2003, 327 : 951-953.
8Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346:393-403.
9Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 2002, 51:2796-2803.
10Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet, 2006, 368 : 1096-1105.
